{"title": "Science k\u00fcrt Immuntherapie gegen Krebs 2013 zum \u201eBreakthrough of the Year\u201c", "author": null, "url": null, "hostname": null, "description": null, "sitename": "IOZK", "date": "2013-04-12", "id": null, "license": null, "body": null, "comments": "Science k\u00fcrt Immuntherapie gegen Krebs 2013 zum \u201eBreakthrough of the Year\u201c/in Externe Meldungen /von IOZK\nBlockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2013-03-21 / Cancer Lett. 2013 Aug;336(2):253-9\nThe oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-\u03b2 signaling/in Hypernephroma, International Publications, Newcastle Disease Virus /von 2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-54\nA low selenium level is associated with lung and laryngeal cancers/in International Publications, Micronutrients /von 2013-03-13 / PLoS One 2013;8(3):e59051\nAllogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study/in Dendritic Cells, Hypernephroma, International Publications /von 2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-27\nThe natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates/in Dendritic Cells, Glioblastoma, International Publications /von 2013-03-01 / Oncoimmunology 2013 Mar;2(3):e23401\nChemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity/in Dendritic Cells, International Publications /von 2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-504\nHarnessing the immune system for the treatment of non-small-cell lung cancer/in International Publications, NSCLC /von 2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-8\nCurrent status of immunotherapy for the treatment of biliary tract cancer/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-72\nVaccine strategies for glioblastoma: progress and future directions/in Dendritic Cells, Glioblastoma, International Publications /von 2013-02-01 / Immunotherapy 2013 Feb;5(2):155-67", "commentsbody": null, "raw_text": null, "text": "https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\nIOZK\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\nIOZK2013-04-12 17:22:322019-02-12 17:22:47Science k\u00fcrt Immuntherapie gegen Krebs 2013 zum \"Breakthrough of the Year\"\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-03-21 / Cancer Lett. 2013 Aug;336(2):253-9\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-03-21 / Cancer Lett. 2013 Aug;336(2):253-92013-03-21 00:00:002019-02-15 08:36:01Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-54\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-542013-03-18 00:00:002013-03-18 00:00:00The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-\u03b2 signaling\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-03-13 / PLoS One 2013;8(3):e59051\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-03-13 / PLoS One 2013;8(3):e590512013-03-13 00:00:002013-03-13 00:00:00A low selenium level is associated with lung and laryngeal cancers\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-27\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-272013-03-04 00:00:002019-02-15 08:48:05Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-03-01 / Oncoimmunology 2013 Mar;2(3):e23401\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-03-01 / Oncoimmunology 2013 Mar;2(3):e234012013-03-01 00:00:002019-02-15 08:47:41The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-504\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-5042013-02-15 00:00:002019-02-15 08:39:50Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-8\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-82013-02-11 00:00:002019-02-15 08:35:16Harnessing the immune system for the treatment of non-small-cell lung cancer\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-72\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-722013-02-01 00:00:002019-02-15 08:45:52Current status of immunotherapy for the treatment of biliary tract cancer\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n0\n0\n2013-02-01 / Immunotherapy 2013 Feb;5(2):155-67\nhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg\n2013-02-01 / Immunotherapy 2013 Feb;5(2):155-672013-02-01 00:00:002019-02-15 08:46:29Vaccine strategies for glioblastoma: progress and future directions", "language": null, "image": null, "pagetype": "website", "links": ["https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.primomedico.com/fr/medecin/iozk-centre-immunologie-et-oncologie-de-cologne/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.primomedico.com/ar/tabib/iozk-mrkz-elm-almnaep-alsrtany-fy-koln/", "mailto:info@iozk.de", "https://www.iozk.de", "https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.iozk.de/", "/", "#", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "#", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "#", "https://www.iozk.de/iozk-publikationen/", "https://www.iozk.de/publikationen/", "https://www.iozk.de/fachwissen/", "https://www.iozk.de/aktuelles/", "https://www.iozk.de/kontakt/", "?s=", "#", "https://www.iozk.de/2013/04/science-kuert-immuntherapie-gegen-krebs-2013-zum-breakthrough-of-the-year/", "https://www.iozk.de/category/iozk-aktuelles/externe-meldungen/", "#", "https://www.iozk.de/2013/04/science-kuert-immuntherapie-gegen-krebs-2013-zum-breakthrough-of-the-year/", "https://www.iozk.de/2013/03/blockade-of-pd-1-pd-l1-immune-checkpoint-during-dc-vaccination-induces-potent-protective-immunity-against-breast-cancer-in-hu-scid-mice/", "https://www.iozk.de/category/publications/checkpoint-inhibitors/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2013/03/blockade-of-pd-1-pd-l1-immune-checkpoint-during-dc-vaccination-induces-potent-protective-immunity-against-breast-cancer-in-hu-scid-mice/", "https://www.iozk.de/2013/03/the-oncolytic-activity-of-newcastle-disease-virus-in-clear-cell-renal-carcinoma-cells-in-normoxic-and-hypoxic-conditions-the-interplay-between-von-hippel-lindau-and-interferon-%ce%b2-signaling/", "https://www.iozk.de/category/publications/hypernephroma/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2013/03/the-oncolytic-activity-of-newcastle-disease-virus-in-clear-cell-renal-carcinoma-cells-in-normoxic-and-hypoxic-conditions-the-interplay-between-von-hippel-lindau-and-interferon-%ce%b2-signaling/", "https://www.iozk.de/2013/03/a-low-selenium-level-is-associated-with-lung-and-laryngeal-cancers/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/micronutrients/", "#", "https://www.iozk.de/2013/03/a-low-selenium-level-is-associated-with-lung-and-laryngeal-cancers/", "https://www.iozk.de/2013/03/allogeneic-partially-hla-matched-dendritic-cells-pulsed-with-autologous-tumor-cell-lysate-as-a-vaccine-in-metastatic-renal-cell-cancer-a-clinical-phase-i-ii-study/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/hypernephroma/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2013/03/allogeneic-partially-hla-matched-dendritic-cells-pulsed-with-autologous-tumor-cell-lysate-as-a-vaccine-in-metastatic-renal-cell-cancer-a-clinical-phase-i-ii-study/", "https://www.iozk.de/2013/03/the-natural-killer-cell-response-and-tumor-debulking-are-associated-with-prolonged-survival-in-recurrent-glioblastoma-patients-receiving-dendritic-cells-loaded-with-autologous-tumor-lysates/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2013/03/the-natural-killer-cell-response-and-tumor-debulking-are-associated-with-prolonged-survival-in-recurrent-glioblastoma-patients-receiving-dendritic-cells-loaded-with-autologous-tumor-lysates/", "https://www.iozk.de/2013/02/chemotherapy-acts-as-an-adjuvant-to-convert-the-tumor-microenvironment-into-a-highly-permissive-state-for-vaccination-induced-antitumor-immunity/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2013/02/chemotherapy-acts-as-an-adjuvant-to-convert-the-tumor-microenvironment-into-a-highly-permissive-state-for-vaccination-induced-antitumor-immunity/", "https://www.iozk.de/2013/02/harnessing-the-immune-system-for-the-treatment-of-non-small-cell-lung-cancer/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/nsclc/", "#", "https://www.iozk.de/2013/02/harnessing-the-immune-system-for-the-treatment-of-non-small-cell-lung-cancer/", "https://www.iozk.de/2013/02/current-status-of-immunotherapy-for-the-treatment-of-biliary-tract-cancer/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/gallbladder-cancer/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2013/02/current-status-of-immunotherapy-for-the-treatment-of-biliary-tract-cancer/", "https://www.iozk.de/2013/02/vaccine-strategies-for-glioblastoma-progress-and-future-directions/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2013/02/vaccine-strategies-for-glioblastoma-progress-and-future-directions/", "https://www.iozk.de/?cat=-1", "https://www.iozk.de/page/103/?cat=-1", "https://www.iozk.de/page/102/?cat=-1", "https://www.iozk.de/page/103/?cat=-1", "https://www.iozk.de/page/105/?cat=-1", "https://www.iozk.de/page/106/?cat=-1", "https://www.iozk.de/page/105/?cat=-1", "https://www.iozk.de/page/225/?cat=-1", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/portfolio-item/evidenzbasierte-medizin-am-iozk/", "https://www.iozk.de/portfolio-item/laboratorien-am-iozk/", "https://www.iozk.de/portfolio-item/magazin-der-iozk-stiftung-consilium/", "https://www.iozk.de/portfolio-item/video-patient-berichtet-ueber-die-erfahrungen-mit-der-iozk-immuntherapie/", "https://www.iozk.de/portfolio-item/video-patientin-frau-ebel-ueber-ihre-erfahrungen-mit-der-iozk-immuntherapie/", "https://www.iozk.de/portfolio-item/video-immunologische-krebstherapie-am-iozk-in-koeln/", "https://www.iozk.de/portfolio-item/informationsbroschuere-der-iozk-stiftung/", "https://www.iozk.de/portfolio-item/personalisierte-medizin-am-iozk/", "https://www.iozk.de/portfolio-item/die-entstehung-von-krebs/", "https://www.iozk.de/portfolio-item/was-bedeutet-immuntherapie/", "https://www.iozk.de/portfolio-item/nobelpreise-fuer-immuntherapie/", "https://www.iozk.de/portfolio-item/curcumin-in-der-medizinischen-anwendung/", "https://www.iozk.de/portfolio-item/virotherapie-mit-viren-gegen-den-krebs/", "https://www.iozk.de/portfolio-item/dendritische-zellen-informieren-das-immunsystem/", "https://www.iozk.de/portfolio-item/hyperthermie-mit-waerme-gegen-krebs/", "https://www.iozk.de/tag/brustkrebs/", "https://www.iozk.de/tag/case-report/", "https://www.iozk.de/tag/check-point-inibitoren/", "https://www.iozk.de/tag/chemotherapie/", "https://www.iozk.de/tag/curamun/", "https://www.iozk.de/tag/curcumin/", "https://www.iozk.de/tag/dendritische-zellen/", "https://www.iozk.de/tag/dr-dirk-lorenzen/", "https://www.iozk.de/tag/dr-wilfried-stuecker/", "https://www.iozk.de/tag/evidenzbasierte-medizin/", "https://www.iozk.de/tag/fluessigbiopsie/", "https://www.iozk.de/tag/german-medical-award/", "https://www.iozk.de/tag/glioblastom/", "https://www.iozk.de/tag/hirntumor/", "https://www.iozk.de/tag/hyperthermie/", "https://www.iozk.de/tag/immuntherapie/", "https://www.iozk.de/tag/io-vac/", "https://www.iozk.de/tag/iozk-symposium/", "https://www.iozk.de/tag/iozk-arbeitsgruppe/", "https://www.iozk.de/tag/iozk-immuntherapie/", "https://www.iozk.de/tag/iozk-patientenbroschuere/", "https://www.iozk.de/tag/iozk-stiftung/", "https://www.iozk.de/tag/newcastle-disease-virus/", "https://www.iozk.de/tag/nobelpreis-fuer-medizin/", "https://www.iozk.de/tag/onkologie/", "https://www.iozk.de/tag/onkolytische-viren/", "https://www.iozk.de/tag/paul-ehrlich-preis/", "https://www.iozk.de/tag/personalisierte-medizin/", "https://www.iozk.de/tag/ponsgliom/", "https://www.iozk.de/tag/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/tag/prostatakrebs/", "https://www.iozk.de/tag/publikationen-dr-wilfried-stuecker/", "https://www.iozk.de/tag/publikationen-prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/tag/publikationen-stefaan-van-gool-md-phd/", "https://www.iozk.de/tag/stefaan-van-gool/", "https://www.iozk.de/tag/target-therapie/", "https://www.iozk.de/tag/virotherapie/", "tel:004922142039925", "mailto:info@iozk.de", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/impressum/", "https://www.iozk.de/datenschutzerklaerung/", "https://www.iozk.de/datenschutz/#BorCook", "https://www.iozk.de/presse/", "#top"]}